Acute Beneficial Hemodynamic Effects of a Novel 3D-Echocardiographic Optimization Protocol in Cardiac Resynchronization Therapy

Carolin Sonne1,*, Lorenz Bott-Flügel2,*, Simon Hauck1, Hasema Lesevic1, Petra Barthel1, Fabian Michalk1, Katharina Hoppe1, Jörg Hausleiter1, Albert Schömig1, Christof Kolb1

1 Klinik für Herz- und Kreislauferkrankungen des Erwachsenen, Deutsches Herzzentrum München, Technische Universität München, Faculty of Medicine, Munich, Germany, 2 Abteilung für Innere Medizin/Kardiologie, Kreiskrankenhaus Erding mit Klinik Dorfen, Erding, Germany

Abstract

Background: Post-implantation therapies to optimize cardiac resynchronization therapy (CRT) focus on adjustments of the atrio-ventricular (AV) delay and ventricular-to-ventricular (VV) interval. However, there is little consensus on how to achieve best resynchronization with these parameters. The aim of this study was to examine a novel combination of doppler echocardiography (DE) and three-dimensional echocardiography (3DE) for individualized optimization of device based AV delays and VV intervals compared to empiric programming.

Methods: 25 recipients of CRT (male: 56%, mean age: 67 years) were included in this study. Ejection fraction (EF), the primary outcome parameter, and left ventricular (LV) dimensions were evaluated by 3DE before CRT (baseline), after AV delay optimization while pacing the ventricles simultaneously (empiric VV interval programming) and after individualized VV interval optimization. For AV delay optimization aortic velocity time integral (AoVTI) was examined in eight different AV delays, and the AV delay with the highest AoVTI was programmed. For individualized VV interval optimization 3DE full-volume datasets of the left ventricle were obtained and analyzed to derive a systolic dyssynchrony index (SDI), calculated from the dispersion of time to minimal regional volume for all 16 LV segments. Consecutively, SDI was evaluated in six different VV intervals (including LV or right ventricular preactivation), and the VV interval with the lowest SDI was programmed (individualized optimization).

Results: EF increased from baseline 23±7% to 30±8 (p<0.001) after AV delay optimization and to 32±8% (p<0.05) after individualized optimization with an associated decrease of end-systolic volume from a baseline of 138±60 ml to 115±42 ml (p<0.001). Moreover, individualized optimization significantly reduced SDI from a baseline of 14.3±5.5% to 6.1±2.6% (p<0.001).

Conclusions: Compared with empiric programming of biventricular pacemakers, individualized echocardiographic optimization with the integration of 3-dimensional indices into the optimization protocol acutely improved LV systolic function and decreased ESV and can be used to select the optimal AV delay and VV interval in CRT.

Introduction

Despite progress in the treatment of heart failure the five year mortality still remains over 50% [1]. About one third of patients with heart failure show a widened QRS complex (≥120 ms) as a sign of conduction system disease [2],[3]. Cardiac resynchronization therapy (CRT) has evolved as the treatment of choice for patients with symptomatic heart failure, left bundle branch block/QRS widening (≥120 ms) and severely reduced systolic left ventricular (LV) function despite optimal medical therapy. Large studies showed that CRT not only improves quality of life and LV systolic function [4,5,6] but also leads to a reduction in mortality [7]. Nevertheless up to one third of patients, so called nonresponders, do not symptomatically respond to this therapy [8,9,10,11]. The exact reasons for lack of response are still unclear, but inadequate lead placement, scar burden, and also device settings may contribute.

Several studies showed that increased scar burden, especially in the posterolateral LV segments, the preferred region of the LV lead positioning, may lead to suboptimal clinical outcome [12,13,14]. This may be due to regional variations in electrical excitability and impulse propagation in proximity of the lead. Transvenous LV lead implantation is limited by the individual anatomy of the tributaries of the coronary sinus and sometimes by
technical aspects concerning the attainability of the target vein. Thus, if one takes into account potential suboptimal LV lead placement, electrical latency during LV stimulation and slowed conduction due to scars near the LV pacing site, all possibly contributing to a reduced response to CRT, an individualized approach to programming CRT systems, with the possibility of pre-activation of either one of the ventricular leads, is intriguing.

In the clinical setting programming of CRT systems is frequently done empirically [15], using an AV delay of 120 ms and simultaneous biventricular pacing, without further optimization.

In small studies it has been shown that optimized programming of the AV delay leads to improved hemodynamics, as well as to improved symptomatic response and LV systolic function in the short and the longer term [16,17],[18,19,20]. As with AV delay, acute hemodynamic benefits [21,22], as well as symptomatic and echocardiographic advantages in the longer term [23,24] have been described with interventricular VV interval optimization.

There are scarce studies that evaluated the effect of a combined approach of AV delay and VV interval optimization [25,26].

The AV delay may be optimized with Doppler echocardiography by evaluating the aortic velocity time integral (AoVTI), which serves as a surrogate for LV stroke volume [18,27,28]. Three dimensional echocardiography (3DE) is an accurate and reproducible method to quantify LV dyssynchrony [29]. It is unclear if an elaborate echocardiographic approach to AV delay and VV interval optimization of CRT systems, including doppler echocardiography (AV delay optimization) and three-dimensional echocardiography (VV interval optimization), leads to an improved acute outcome after CRT initiation.

In the present study we therefore evaluated the feasibility of three-dimensional echocardiography (3DE) to optimize the interventricular interval of biventricular pacemakers.

Methods

Ethics statement

All patients included in this study gave written informed consent prior to entry into the study. The study complies with the principles of the Declaration of Helsinki and was approved by the institutional ethics committee of Deutsches Herzzentrum München, Technical University of Munich, the only institution, where participants were recruited and this study was conducted (Az 2608/09; 10.12.2009).

Study design

In this study we prospectively included patients who underwent CRT implantation according to 2006 guidelines [30] (ejection fraction <35%, New York Heart Association (NYHA) functional class III or IV despite optimal pharmacological therapy, and QRS duration >120 ms). At the time of inclusion baseline parameters were assessed (medication status, ECG, and echocardiography). All patients underwent a comprehensive evaluation with 3D echocardiography before implantation (baseline). The day after implantation the device was optimized as described below. Finally, LV function was again assessed echocardiographically.

Echocardiography

Routine baseline 2D and 3D echocardiography (Philips iE33) were performed in all patients according to institutional guidelines. 3D echocardiography was performed using the X3-1 matrix transducer. Apical views were optimized to allow complete visualization of the left ventricle in the 4- and 2-chamber views. During breath-hold a complete 3D volume was acquired during 7 to 8 cardiac cycles. Angle and depth were minimized to ensure optimal temporal resolution while still acquiring the entire LV volume. The volume data were sent to a workstation for off-line processing and analysis (QLab v. 6.0, Philips), using the 3DQ-Advanced plugin. The software allows semi-automated delineation of end-systolic and end-diastolic endocardial borders (Figure 1). Through automated sequential tracking throughout the cardiac cycle the software creates a dynamic 3D model of the left ventricular cavity. The software calculates ejection fraction, end-diastolic and end-systolic volumes, as well as the systolic dyssynchrony index (SDI). The latter is calculated as the standard deviation of the time to minimal systolic volume (Tmin) in 16 segments, excluding the apical cap in a standard 17-segment model. The SDI is corrected for the RR interval and is expressed as a percentage (Figure 1).

Echocardiographic guided optimization of the CRT device was performed the day after implantation. First, AV delays were analyzed from 80 to 200 ms, with steps of 20 ms. Aortic flow was recorded as a velocity-time integral (AoVTI) using continuous-wave Doppler at the level of the aortic valve, according to the consensus statement of the American Society of Echocardiography [31]. Subsequently, the AV delay with the highest velocity-time integral was programmed. Interventricular intervals between the right and left ventricles (VV intervals) were analyzed at 5 different intervals: simultaneous stimulation (LV = RV), left-ventricular pre-activation (LV+20, LV+40 ms), and right-ventricular pre-activation (RV+20, RV+40 ms). For each of the tested intervals a complete 3D full volume was acquired. Analysis of the 3D volume data was done off-line in a blinded fashion by 2 independent investigators. The device was programmed for the VV interval with the lowest SDI (Figure 1).

Statistical analysis

All continuous variables are expressed as mean ± standard deviation. Presence of a normal distribution was evaluated by Kolmogorov-Smirnov test, means were compared by paired t-test. Where a non-parametric distribution was assumed, Wilcoxon test was performed. Categorical variables were tested by the chi-square test. To assess intra- and inter-observer variabilities, intra-class correlations (ICC) were calculated, and the variability is expressed as the absolute difference between 2 measurements divided by the average of the 2 measurements. Resulting p-values<0.05 were considered statistically significant.

Results

Baseline characteristics

A total of 25 patients were included in the study. The mean age was 67 years with 56% males (Table 1). 56% had ischemic cardiomyopathy as the underlying cause of heart failure. Further baseline characteristics are given in Table 1.

AV delay optimization

For AV delay optimization aortic velocity time integral (AoVTI) was examined in eight different AV delays, and the AV delay with the highest AoVTI was programmed. Aortic flow increased from baseline 24±7 cm to 27±9 cm after AV delay optimization (p<0.05). The optimal mean sensed AV delay programmed was 108 ms [80–140 ms] and the optimal paced AV delay programmed was 133 ms [120–140 ms]. The SDI improved significantly from 14.3±5.3% to 9.0±6.8%, as well as the EF, which rose from a baseline value of 23±7% to 30±8% after AV delay optimization (Table 2, Figure 2).
VV interval optimization

After AV delay optimization, the VV intervals were analyzed by evaluating the 3D full volume datasets. For each VV interval a separate 3D dataset was analyzed. The VV interval with the lowest corresponding SDI was used for programming the device.

We observed a further decrease in SDI values from 9.0±4.6% to 6.1±2.6% (Table 2). In most patients either simultaneous activation of left and right ventricle or mild pre-activation of the left ventricle resulted in the smallest SDI value (simultaneous activation in 28%, LV pre-activation by 20 ms in 48% of all patients). In 3 patients LV pre-activation by 40 ms, and in 3 patients right ventricular pre-activation by 20 ms led to the best SDI, and were programmed accordingly. Interestingly, the ejection fraction increased from 23±7% before pacemaker implantation to 30±8% after AV delay optimization and we could observe a further significant improvement after VV interval optimization (after complete optimization: 32±8%). The aortic VTI, which rose from baseline 24±7 to 27±9 cm after AV optimization, remained unchanged after VV interval optimization (26± cm). The end-diastolic volume fell from baseline 176±62 ml to 166±48 ml after complete optimization. The end-systolic volume also showed a significant reduction (baseline 138±60 ml, after complete optimization 115±42 ml; Table 2, Figure 2).

**Figure 1. 3D-echocardiography guided optimization of cardiac resynchronization therapy.** Patient with ischemic cardiomyopathy, severely reduced systolic left ventricular (LV)-function (EF 16.8%), left bundle branch block and dyspnea on exertion (NYHA class III) selected for cardiac resynchronization therapy (CRT) before biventricular pacemaker implantation: A) tracing of the LV endocardial boundary in the multiple apical and short axis views. From these datasets a volumetric model of the left ventricle is drawn (B), and time-volume curves are automatically integrated for each segment: C) time-volume curves of the patient before pacemaker implantation (upper panel); immediately after implantation (middle panel); after complete echocardiographic optimization (lower panel). Shown are the respective SDI values after each optimization step.

doi:10.1371/journal.pone.0030964.g001
Intra- and inter-observer agreement was generally very good. Intra-observer variability in measured SDI was 14±8%. Intra-observer variability in ejection fraction, end-diastolic volume, and end-systolic volume was 3±2%, 2±2%, and 3±3%, respectively. Intra-class correlation coefficients were 0.974 for SDI, 0.997 for EF, 0.998 for EDV and 0.998 for ESV.

Inter-observer variability in measured SDI was 17±14%. Inter-observer variability in ejection fraction, end-diastolic volume, and end-systolic volume was 8±6%, 5±4%, and 4±3%, respectively. Intra-class correlation coefficients were 0.948 for SDI, 0.901 for EF, 0.997 for EDV and 0.996 for ESV.

Discussion

In the present study we tested a new protocol of combined AV delay and VV interval optimization of CRT-systems including standard Doppler-echocardiography for AV delay, and 3D echocardiography for VV interval optimization. This elaborate protocol led to a significant improvement of LV function immediately after implantation of a CRT device compared to empiric device programming. The examined cohort consisted of typical candidates for cardiac resynchronization therapy. All were highly symptomatic and on recommended optimal pharmacological therapy. Moreover, all patients showed QRS prolongation of more than 120 ms, and had a mean ejection fraction of 23%.

After the first step of optimization (AV delay optimization) the ejection fraction rose from 23% to 30% and could be increased even further by VV interval optimization (32%). End-systolic volume was reduced significantly already after AV delay optimization, with a moderate further reduction after VV interval optimization. The SDI, as a marker of interventricular dyssynchrony, fell sharply after each optimization step, whereas the aortic VTI, a surrogate marker of stroke volume, was only affected by AV delay optimization. In most patients the VV interval had to be programmed differently from the standard setting (i.e. simultaneous activation of left and right ventricle), only 28% of patients achieved the lowest possible SDI with the standard setting of simultaneous activation of left and right ventricle, only 28% of patients achieved the lowest possible SDI with the standard setting of simultaneous activation of left and right ventricle, only 28% of patients achieved the lowest possible SDI with the standard setting of simultaneous activation of left and right ventricle.

These results strongly support an individualized optimization of CRT-systems, specifically tailored to the patients. CRT is used in patients with various etiologies of severe symptomatic heart failure [9] [32], and one can imagine that a one fits all approach may not necessarily generate the best outcome. This has also been shown in a small cohort with Doppler optimization of AV delay and VV interval. Favorable hemodynamic response was more pronounced in the group of patients randomized to the optimization protocol [33].

This is the first study to use 3DE for VV interval optimization. The only modest further improvement of LV-EF after VV interval optimization in addition to AV optimization was lower than

| Table 1. Baseline characteristics. |
|----------------------------------|
| N = 25                           |
| **Demographic data**             |
| Age, years                       | 67±11 |
| Male sex                         | 14 (56%) |
| **Clinical data**                |
| NYHA class 3                     | 22 (88%) |
| NYHA class 4                     | 3 (12%) |
| Ischemic CMP                     | 14 (56%) |
| **Medication**                   |
| Betablockers                     | 23 (92%) |
| ACE-inhibitors/ARBs              | 23 (92%) |
| Diuretics                        | 24 (96%) |
| Aldosterone antagonists          | 18 (72%) |
| Digitalis                        | 3 (12%) |
| Statins                          | 25 (100%) |
| **Electrocardiographic data**    |
| QRS width, ms (median; IQR)      | 160 (122–198) |
| **Echocardiographic data**       |
| LV end-diastolic volume, ml      | 176±62 |
| LV end-systolic volume, ml       | 138±60 |
| LV-EF, %                         | 23±7 |
| SDI, %                           | 14.3±5.5 |

Values are shown as means ± standard deviation or count (percentage). NYHA, New York Heart Association; CMP, cardiomyopathy; ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; LV, left ventricle; SDI, systolic dyssynchrony index.

doi:10.1371/journal.pone.0030964.t001

Only 28% of patients achieved the lowest possible SDI with the standard setting of simultaneous activation of left and right ventricle. 86% of patients with ischemic cardiomyopathy needed pre-activation versus only 55% of patients with dilated cardiomyopathy (p<0.05, Figure 3).

Intra- and inter-observer agreement

The intra- and inter-observer agreement was generally very good. Intra-observer variability in measured SDI was 14±8%. Intra-observer variability in ejection fraction, end-diastolic volume, and end-systolic volume was 3±2%, 2±2%, and 3±3%, respectively. Intra-class correlation coefficients were 0.974 for SDI, 0.997 for EF, 0.998 for EDV and 0.998 for ESV.

Inter-observer variability in measured SDI was 17±14%. Inter-observer variability in ejection fraction, end-diastolic volume, and end-systolic volume was 8±6%, 5±4%, and 4±3%, respectively. Intra-class correlation coefficients were 0.948 for SDI, 0.901 for EF, 0.997 for EDV and 0.996 for ESV.

Table 2. Echocardiographic parameters at baseline and after AV delay and VV interval optimization.

|                             | Baseline       | After AV delay optimization | After complete optimization |
|-----------------------------|----------------|----------------------------|----------------------------|
| LV end-diastolic volume, ml | 176±62         | 168±50                     | 166±48                     |
| LV end-systolic volume, ml  | 138±60         | 121±48†                    | 115±42*                    |
| Ejection fraction, %        | 23±7           | 30±8†                      | 32±8*                      |
| SDI, %                      | 14.3±5.5       | 9.0±4.1†                   | 6.1±2.65*                  |
| Aortic VTI, cm              | 24±7           | 27±9†                      | 26±8*                      |

SDI, systolic dyssynchrony index; AV, atrio-ventricular; VV, ventriculo-ventricular; LV, left ventricular; VTI, velocity-time integral.

Shown are means ± standard deviation.

†p<0.001: for comparison of AV optimization vs baseline.

∗p<0.05: for comparison of complete optimization vs AV optimization only.

∗p<0.05: for comparison of complete optimization vs baseline.

doi:10.1371/journal.pone.0030964.t002

3D-Echocardiography Guided CRT-Optimization

February 2012 | Volume 7 | Issue 2 | e30964
anticipated. Nevertheless, the pronounced decrease of the systolic
dysynchrony index (SDI) with each optimization step was striking
and may lead to further improvement of LV-EF in the long-term.
It is also known from a small study by Valzania et al. [34], that
hemodynamic parameters tend to change over the course of
several months after CRT. So, it would be very interesting, if these
modest changes in EF immediately after implantation translate
into robust changes later on in the course. Further follow-up has to
clarify this issue.

The positive acute results are especially encouraging as LV
resynchronization acutely after the implantation of biventricular
pacemakers predicts response to CRT in the long-term [35].
Moreover a recent study by Kapetanakis et al. emphasized the
relevance of the left ventricular systolic dyssynchrony index (SDI)
with respect to patient selection for CRT [36]. They found SDI to
be highly predictive of response to CRT, in terms of functional
(NYHA functional class) and echocardiographic (LV-EF and LV
end-systolic volume) improvement. Similarly, we found a trend
towards more pronounced acute echocardiographic response with
the suggested cutoff value for the baseline SDI of 10.4% (change in
EF: 7 +/- 5% in the low SDI vs 10 +/- 4% in the high SDI
subgroup, p = 0.1; change in ESV: -13 +/- -13 ml in the low vs.
-26 +/- -30 ml in the high SDI subgroup, p = 0.2). Future studies
should investigate if this highly promising optimization technique
combined with improved selection criteria including an SDI cut-
off would translate into improved functional outcome.

Furthermore, AV delay optimization can maximize the benefits
of cardiac resynchronization therapy. If programmed poorly, it
may curtail beneficial effects of VV interval optimization and of
CRT in general. Optimized AV synchrony is achieved by an AV
delay that provides the best left atrial contribution to LV filling
resulting in maximum stroke volume. Several echocardiographic
methods have been used for AV delay optimization [16,17]. In our
study, we used the aortic VTI Doppler method to optimize the AV
delay. It produces reproducible results and has been shown to be
superior to the mitral inflow method [37].

VV interval optimization has been attempted with several
techniques with varying success [21,22,24,25,33,38]. The high
percentage of patients with sequential inter-ventricular pacing as
the optimal setting is in concordance with other studies that
evaluated VV interval optimization [22,23,24,25,39].

The SDI seems to be a promising parameter for VV interval
optimization, as it may help to overcome the problems arising
from LV-lead latency and from slowed conduction due to
increased scar burden in patients with ischemic cardiomyopathy
[13,14]. Simultaneous pacing of both ventricles may result in
suboptimal resynchronization due to an unbalanced activation of
right ventricular and left ventricular wavefronts. SDI helps in
finding and programming the optimal VV interval with either left
or right ventricular pre-activation to compensate for these
challenges and thus resulting in a more synchronous mechanical
activation of both ventricles. Moreover, in a patient where the only

**Figure 2. Acute hemodynamic effects of 3D-echocardiography guided optimization.** Hemodynamic variables for each timestep of the
optimization protocol: A) systolic dyssynchrony index, B) ejection fraction, and C) left-ventricular end-diastolic and end-systolic volumes. Shown are
means +/- standard deviation. * p<0.05 vs. baseline values.
doi:10.1371/journal.pone.0030964.g002
References

1. Levy D, Kuchtaish S, Larson MG, Benjamin EJ, Kupka MJ, et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397–1402.

2. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN (2002) QRS duration and mortality in patients with congestive heart failure. Am Heart J 143: 1083–1091.

3. Kashani A, Barold SS (2003) Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 46: 2183–2192.

4. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, et al. (2002) Long-term benefits of biventricular pacing in congestive heart failure: results from the MUniste STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40: 111–118.

5. Sahlike TV, Dimopoulos K, Francis D (2004) Cardiac resynchronisation may reduce all-cause mortality: meta-analysis of preliminary COMPANION data with CONTACT-CD, InSync ICD, MIRACLE and MUSTIC. Int J Cardiol 93: 101–103.

6. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, et al. (2003) Combined cardiac resynchronisation and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289: 2685–2694.

7. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, et al. (2005) The effect of cardiac resynchronisation on morbidity and mortality in heart failure. N Engl J Med 352: 1539–1549.

8. Bax JJ, Bleeker GB, Marwick TH, Molhoek SG, Boersma E, et al. (2004) Left ventricular dysynchrony predicts response and prognosis after cardiac resynchronisation therapy. J Am Coll Cardiol 44: 1854–1860.

9. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, et al. (2002) Cardiac resynchronisation in chronic heart failure. N Engl J Med 346: 1845–1853.

10. Molhoek SG, Vane L, Bootsea M, Steendijk P, Van Der Wall EE, et al. (2004) QRS duration and shortening to predict clinical response to cardiac resynchronisation therapy in patients with end-stage heart failure. Pacing Clin Electrophysiol 27: 308–313.

11. Reuter S, Garrigue S, Barold SS, Jais P, Hocini M, et al. (2002) Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. Am J Cardiol 89: 346–350.

12. Hummel JP, Linderer JR, Belčik JT, Ferguson JD, Mangrum JM, et al. (2005) Extent of myocardial viability predicts response to biventricular pacing in ischemic cardiomyopathy. Heart Rhythm 2: 1211–1217.

13. Bleeker GB, Kaandorp TA, Lamh BJ, Boersma E, Steendijk P, et al. (2006) Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronisation therapy. Circulation 113: 968–976.

14. Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, et al. (2007) Impact of viability and scar tissue on response to cardiac resynchronisation therapy in ischaemic heart failure patients. Eur Heart J 28: 33–41.

Conclusion

In the present study we could demonstrate, that an individualized echocardiographic optimization with the integration of 3-dimensional indices into the optimization protocol significantly improves LV function in CRT compared to empiric VV interval programming. This novel individualized echocardiographic optimization protocol can be used to select the optimal AV delay and VV interval in CRT.

Acknowledgments

The authors would like to thank all colleagues who contributed to this study. We are grateful to Drs. Gabriele Demetz and Daniel Braum for their invaluable contribution.

Author Contributions

Conceived and designed the experiments: CS LB-F SH JH AS CK. Performed the experiments: CS SH HL PB FM KH. Analyzed the data: CS LB-F CK. Wrote the paper: CS LB-F CK.
15. Gras D, Gupta MS, Bouloge E, Guzzo L, Abraham WT (2009) Optimization of AV and VV delays in the real-world CRT patient population: an international survey on current clinical practice. Pacing Clin Electrophysiol 32 Suppl 1: S236–239.

16. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, et al. (1999) Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 99: 2993–3001.

17. Jansen AH, Bracke FA, van Dantzij JM, Meijer A, van der Voort PH, et al. (2006) Correlation of echo-Doppler optimization of atrioventricular delay in cardiac resynchronization therapy with invasive hemodynamics in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 97: 532–537.

18. Sawhney NS, Waggoner AD, Garhwal S, Ghavda MK, Osborn J, et al. (2004) Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. Heart Rhythm 1: 562–567.

19. Harth SE, Yaudi SH, Baser A, Flasch A, Korosoglou G, et al. (2007) Immediate and chronic effects of AV-delay optimization in patients with cardiac resynchronization therapy. Int J Cardiol 115: 318–325.

20. Morales MA, Sturati U, Pancheti L, Rossi A, Pacenti M (2006) Atrioventricular delay optimization by doppler-derived left ventricular dP/dt improves 6-month outcome of resynchronized patients. Pacing Clin Electrophysiol 29: 564–568.

21. Erdner M, Ring M, Sariev T (2010) Sequential biventricular pacing improves regional contractility, longitudinal function and dysynchrony in patients with heart failure and prolonged QRS. Cardiovasc Ultrasound 8: 12.

22. Phillips KP, Harberts DB, Johnston LP, O’Donnell D (2007) Left ventricular resynchronization predicted by individual performance of right and left univentricular pacing: a study on the impact of sequential biventricular pacing on ventricular dyssynchrony. Heart Rhythm 4: 147–153.

23. Sogaard P, Egeblad H, Pedersen AK, Kim WY, Kristensen BO, et al. (2002) Sequential versus simultaneous left ventricular pacing: a randomized prospective trial of AV delay optimization in patients with congestive heart failure: the Pacing Therapies for Congestive Heart Failure Research Group. Circulation 99: 2993–3001.

24. Leon AR, Abraham WT, Brozena S, Daubert JP, Fisher WG, et al. (2005) Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failure: evaluation by tissue Doppler imaging. Circulation 106: 2078–2084.

25. Vidal B, Bouloge E, Guzzo L, Abraham WT (2009) Optimization of cardiac resynchronization therapy: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 112: 992–1000.

26. Sawhney NS, Waggoner AD, Garhwal S, Ghavda MK, Osborn J, et al. (2004) Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. Heart Rhythm 1: 562–567.

27. Gras D, Gupta MS, Bouloge E, Guzzo L, Abraham WT (2009) Optimization of AV and VV delays in the real-world CRT patient population: an international survey on current clinical practice. Pacing Clin Electrophysiol 32 Suppl 1: S236–239.

28. Valzania C, Biffi M, Martignani C, Dierenger I, Bertini M, et al. (2007) Cardiac resynchronization therapy: multiple options and guidelines. Clinical and research aspects. Eur Heart J 28: 2136–2144.

29. Kapetanakis S, Kearney MT, Siva A, Gall N, Coodlin M, et al. (2005) Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 112: 992–1000.

30. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Champion B, et al. (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the management of patients with the wide complex tachycardia: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48: e247–346.

31. Gorcsan J, 3rd, Abraham T, Jagdr DA, Bax JJ, Derumeaux G, et al. (2006) Echocardiography for cardiac resynchronization therapy: recommendations for performance and reporting—a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr 21: 191–213.

32. Ypenburg C, Westenberg JJ, Bleeker GB, Van de Veire N, Marsan NA, et al. (2008) Noninvasive imaging in cardiac resynchronization therapy—part 1: selection of patients. Pacing Clin Electrophysiol 31: 1475–1499.

33. Bonani G, Biffi M, Muller CP, Scisli KH, Grove R, et al. (2009) A prospective randomized evaluation of VV delay optimization in CRT-D recipients: echocardiographic observations from the RHYTHM II ICD study. Pacing Clin Electrophysiol 32 Suppl 1: S120–125.

34. Valzania C, Biffi M, Martignani C, Dierenger I, Bertini M, et al. (2007) Cardiac resynchronization therapy: multiple options and guidelines. Clinical and research aspects. Eur Heart J 28: 2136–2144.

35. Bleeker GB, Mollena SA, Holman ER, Van de Veire N, Ypenburg C, et al. (2007) Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation 116: 1440–1440.

36. Kapetanakis S, Bhan A, Margastoel F, Kearney MT, Gall N, et al. (2011) Real-time 3D echo in patient selection for cardiac resynchronization therapy. JACC Cardiovascular imaging 4: 16–26.

37. Kerlan JE, Sawhney NS, Waggoner AD, Garhwal S, Ghavda MK, Osborn J, et al. (2006) Cardiac resynchronization therapy: a randomized prospective comparison of echocardiographic measurements for optimizing cardiac resynchronization therapy: stroke distance is best. Eur J Heart Fail 11: 779–788.

38. Zhao R, Yu Y, He X, Nie D (2006) Correlation of echo-Doppler optimization of atrioventricular delay in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Circulation 99: 2993–3001.

39. Parreira L, Santos JF, Madeira J, Mendes L, Seixo F, et al. (2005) Cardiac resynchronization therapy with sequential biventricular pacing: impact of echocardiographic observations from the RHYTHM II ICD study. Pacing Clin Electrophysiol 32 Suppl 1: S120–125.

40. Kapetanakis S, Kearney MT, Siva A, Gall N, Coodlin M, et al. (2005) Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 112: 992–1000.

41. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Champion B, et al. (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the management of patients with the wide complex tachycardia: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48: e247–346.

42. Gorcsan J, 3rd, Abraham T, Agler DA, Bax JJ, Derumeaux G, et al. (2006) Echocardiography for cardiac resynchronization therapy: recommendations for performance and reporting—a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr 21: 191–213.

43. Ypenburg C, Westenberg JJ, Bleeker GB, Van de Veire N, Marsan NA, et al. (2008) Noninvasive imaging in cardiac resynchronization therapy—part 1: selection of patients. Pacing Clin Electrophysiol 31: 1475–1499.

44. Bonani G, Biffi M, Muller CP, Scisli KH, Grove R, et al. (2009) A prospective randomized evaluation of VV delay optimization in CRT-D recipients: echocardiographic observations from the RHYTHM II ICD study. Pacing Clin Electrophysiol 32 Suppl 1: S120–125.

45. Valzania C, Biffi M, Martignani C, Dierenger I, Bertini M, et al. (2007) Cardiac resynchronization therapy: multiple options and guidelines. Clinical and research aspects. Eur Heart J 28: 2136–2144.

46. Kerlan JE, Sawhney NS, Waggoner AD, Garhwal S, Ghavda MK, Osborn J, et al. (2006) Cardiac resynchronization therapy: a randomized prospective comparison of echocardiographic measurements for optimizing cardiac resynchronization therapy: stroke distance is best. Eur J Heart Fail 11: 779–788.

47. Zhao R, Yu Y, He X, Nie D (2006) Correlation of echo-Doppler optimization of atrioventricular delay in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Circulation 99: 2993–3001.